(NASDAQ: GALT) Galectin Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 9.74%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.81%.
Galectin Therapeutics's earnings in 2025 is -$45,308,000.On average, 1 Wall Street analyst forecast GALT's earnings for 2025 to be -$42,405,362, with the lowest GALT earnings forecast at -$42,405,362, and the highest GALT earnings forecast at -$42,405,362. On average, 1 Wall Street analyst forecast GALT's earnings for 2026 to be -$41,139,530, with the lowest GALT earnings forecast at -$41,139,530, and the highest GALT earnings forecast at -$41,139,530.
In 2027, GALT is forecast to generate -$45,569,941 in earnings, with the lowest earnings forecast at -$45,569,941 and the highest earnings forecast at -$45,569,941.